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The low-density lipoprotein receptor (LDLR)-related protein (LRP) is a multiligand endocytic
receptor that has broad cellular and physiological functions. Previous studies have shown that
both tyrosine-based and di-leucine motifs within the LRP cytoplasmic tail are responsible for
mediating its rapid endocytosis. Little is known, however, about the mechanism by which LRP is
targeted for degradation. By examining both endogenous full-length and a minireceptor form of
LRP, we found that proteasomal inhibitors, MG132 and lactacystin, prolong the cellular half-life
of LRP. The presence of proteasomal inhibitors also significantly increased the level of LRP at the
cell surface, suggesting that the delivery of LRP to the degradation pathway was blocked at a
compartment from which recycling of the receptor to the cell surface still occurred. Immunoelectron microscopy analyses demonstrated a proteasomal inhibitor-dependent reduction in LRP
minireceptor within both limiting membrane and internal vesicles of the multivesicular bodies,
which are compartments that lead to receptor degradation. In contrast to the growth hormone
receptor, we found that the initial endocytosis of LRP minireceptor does not require a functional
ubiquitin–proteasome system. Finally, using truncated cytoplasmic mutants of LRP minireceptors, we found that a region of 19 amino acids within the LRP tail is required for proteasomal
regulation. Taken together our results provide strong evidence that the cellular turnover of a cargo
receptor, i.e., LRP, is regulated by the proteasomal system, suggesting a broader function of the
proteasome in regulating the trafficking of receptors into the degradation pathway.

INTRODUCTION
The low-density lipoprotein receptor (LDLR)-related protein
(LRP) is a large endocytic receptor that belongs to the emerging LDLR family (Herz et al., 1988; Herz and Strickland,
2001). LRP is a unique receptor in the family because of its
ability to bind and endocytose a variety of structurally and
functionally distinct ligands and its important role during
embryonic development and the pathogenesis of various
Article published online ahead of print. Mol. Biol. Cell 10.1091/
mbc.E02– 03– 0152. Article and publication date are at www.molbiolcell.org/cgi/doi/10.1091/mbc.E02– 03– 0152.
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diseases (reviewed in Krieger and Herz, 1994; Hussain et al.,
1999; Herz, 2001; Herz and Strickland, 2001). Ligands of LRP
include proteins that are involved in lipid metabolism, proteinase regulation, blood coagulation/fibrinolysis cascades,
and several membrane proteins, including urokinase plasminogen activator receptor (uPAR) and ␤-amyloid precursor protein (APP). LRP’s extracellular domain contains 31
ligand-binding repeats grouped into four clusters of 2, 8, 10,
and 11 repeats, respectively (Herz et al., 1988; Krieger and
Herz, 1994). However, only the second and the fourth clusters have been shown to mediate ligand binding (Willnow et
al., 1994; Neels et al., 1999; Obermoeller-McCormick et al.,
2001). The extracellular domain of LRP precedes a single
membrane-spanning segment, which is followed by a 100amino acid cytoplasmic tail. Biochemical studies have
shown that LRP is synthesized as a single polypeptide chain
of ⬃600 kDa that is cleaved by furin in the trans-Golgi
compartments into two subunits of 515 and 85 kDa, which
remain associated noncovalently with one another as they
3325
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mature to the cell surface (Herz et al., 1990; Willnow et al.,
1996).
Another significant feature of LRP is its rapid endocytosis
(Li et al., 2000, 2001a) when compared with that of other
members of the LDLR family. Although two copies of the
NPxY motif, which has been shown to mediate LDLR endocytosis (Chen et al., 1990), are present within the LRP tail,
recent studies from our laboratory have shown that the
primary endocytosis signals for LRP are a YxxL motif and a
di-leucine motif (Li et al., 2000). Our studies have also shown
that the initial endocytosis of LRP is further regulated by
cyclic AMP– dependent protein kinase A (PKA) phosphorylation on a serine residue within LRP’s cytoplasmic tail (Li et
al., 2001b). These studies together indicate that the endocytic
trafficking of LRP is unique compared with other LDLR
family members.
Previous studies on LRP trafficking have focused on the
early secretory pathway and the early events of endocytosis
(Li et al., 2000; Bu, 2001). However, little is known regarding
the trafficking of LRP to the degradation pathway. The ubiquitin–proteasome system plays an important role in mediating both receptor endocytosis and sorting to the degradation pathway for several cell surface receptors (Hicke, 1997;
Strous and Govers, 1999; Lemmon and Traub, 2000; Hicke,
2001). Although polyubiquitination of proteins leads to their
degradation via the 26S proteasome (Hershko and Ciechanover, 1998), monoubiquitination has recently been shown
to modulate the function and trafficking of various cellular
proteins (Hicke, 2001; Katzmann et al., 2001). To date the
most definitively studied examples of the involvement of the
ubiquitin–proteasome regulation of cell surface receptor include the yeast G protein-coupled receptors (Hicke and
Riezman, 1996; Terrell et al., 1998; Shih et al., 2000), the
growth hormone receptor (GHR; Strous et al., 1996; van
Kerkhof et al., 2000), the human epidermal growth factor
receptor (EGFR; Levkowitz et al., 1998; Yokouchi et al., 1999;
Longva et al., 2002) and the mammalian ␤2-adrenergic receptor (Shenoy et al., 2001). In case of the GHR, it was found
that although ubiquitination of GHR itself is not required,
functional ubiquitination and proteasomal systems are both
essential for its endocytosis and trafficking to the degradation pathway (Strous and Govers, 1999).
Despite recent evidence for the engagement of LRP in
several signal transduction pathways (Goretzki and Mueller,
1998; Trommsdorff et al., 1998; Zhuo et al., 2000; Herz, 2001;
Boucher et al., 2002; Loukinova et al., 2002), the multiple
ligands for and rapid endocytosis rate of LRP suggest that a
major function of this receptor is the cellular transport of
ligands via receptor-mediated endocytosis. To examine
whether the transport of such a signal transducing/cargo
receptor is regulated by the ubiquitin–proteasome system,
we analyzed the effects of proteasomal inhibitors on the
endocytic trafficking and cellular turnover of LRP. We found
that the delivery of LRP to the degradation pathway is
blocked within a compartment from which recycling of the
receptor still occurs.

et al., 1993). All tissue culture media, sera, and plastic supplies were
from Life Technologies (Grand Island, NY). Na125I was purchased
from NEN Life Sciences (Boston, MA). [35S]Cysteine was from ICN
(Costa Mesa, CA). IODO-GEN reagent was from Pierce (Rockford,
IL). MG132 (Z-Leu-leu-leu-H aldehyde) proteasomal inhibitor was
from Peptide Institute, Inc (Minosh-shi Osaka, Japan). Clasto-lactacystin-␤-lactone (referred to as lactacystin in this manuscript) proteasomal inhibitor was from Calbiochem-Novabiochem (La Jolla,
CA). Complete protease inhibitor cocktail (Complete) was from
Roche (Indianapolis, IN). Mouse anti-HA antibody was from Babco
(12CA5; Richmond, CA). FITC-conjugated goat anti-mouse antibody was from BD Biosciences-PharMingen (San Diego, CA).
Horseradish peroxidase–linked anti-mouse antibody, ECL detection
system, and Rainbow molecular size markers were from Amersham
Pharmacia Biotech (Piscataway, NJ). All other chemicals were reagent grade and from Sigma (St. Louis, MO).

Cell Culture
Human hepatoma HepG2 cells (Bu et al., 1993) were cultured in
minimum essential medium (MEM) supplemented with 10% fetal
bovine serum, 100 U/ml penicillin, 100 g/ml streptomycin, and
300 g/ml l-glutamine. Chinese hamster ovary (CHO)-K1 and
CHO LRP-null cells (FitzGerald et al., 1995) were cultured in F-12
Ham’s media with 10% fetal bovine serum, 100 U/ml penicillin, 100
g/ml streptomycin, and 300 g/ml l-glutamine. Ts20 cells
(Handley-Gearhart et al., 1994) were grown in MEM␣ supplemented
with 10% fetal calf serum, 4.5 g/l glucose, 100 U/ml penicillin, and
100 g/ml streptomycin. CHO-mLRP4, ts20-mLRP4, and ts20-GHR
cells were cultured under the same conditions as their parent CHO
cells, except with the addition of 350 g/ml (for CHO-mLRP4 cells)
or 450 g/ml (for ts20-mLRP4 and ts20-GHR cells) geneticin. Ts20
cells were maintained at 30°C; all others were maintained at 37°C in
a humidified incubator with 5% CO2.

Metabolic Pulse-chase Labeling and
Immunoprecipitation
HepG2, CHO-K1, or CHO-mLRP4 cells were seeded at 5 ⫻ 105
cells/well density in six-well plates and cultured overnight before
experiments. HepG2 cells transiently transfected with mLRP4 by
calcium phosphate method were replated after overnight transfection and cultured for an additional 24 h before experiments. Metabolic pulse-chase labeling of LRP or mLRP4 with [35S]cysteine was
performed essentially as described before (Bu et al., 1992, 1995).
Briefly, after depletion of endogenous cysteine, cells were pulselabeled with [35S]cysteine (200 Ci/ml) in cysteine-free MEM and
chased with serum-containing medium in the presence or absence
of 20 M MG132 for various times as indicated in each experiment.
Cells were then lysed at 4°C in 0.5 ml PBSc (phosphate-buffered
saline supplemented with 1 mM CaCl2 and 0.5 mM MgCl2) containing 1% Triton X-100, 1 mM PMSF, 1⫻ Complete, and 10 mM
N-ethymaleimide (NEM; lysis buffer). Cell lysates were incubated
with an excess of either anti-LRP antibody (for endogenous LRP
with HepG2 cells) or monoclonal anti-HA antibody (for mLRP4
with CHO-mLRP4 cells), followed with protein-A agarose beads.
Immunoprecipitated protein was released from the beads by boiling
in Laemmli sample buffer under reducing conditions (Laemmli,
1970) and analyzed via SDS-PAGE. Band intensities were quantitated using a phosphoimager (Storm 840; Molecular Dynamics,
Sunnyvale, CA).

Western Blotting of LRP Minireceptor
MATERIALS AND METHODS
Materials
Recombinant human RAP was produced as a glutathione S-transferase fusion protein and purified as described before (Warshawsky
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CHO-mLRP4 cells or CHO LRP-null cells stably transfected with
mLRP4 tail truncation mutants (Li et al., 2000) were seeded at 1.5 ⫻
106 cells per 60-mm dish and cultured overnight before experiments. Cells were incubated in the presence or absence of proteasome inhibitors (20 M MG132 or lactacystin) at 37°C as indicated
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rum-free medium and incubated with or without proteasomal inhibitors (20 M MG132 or lactacystin) for varying lengths of time.
Cells were then detached by incubation with nonenzymatic cell
dissociation solution (Sigma). Successive incubations with affinitypurified anti-HA IgG (25 g/ml) and goat anti-mouse Ig-FITC were
carried out at 4°C for 45 min each. Background fluorescence intensity was assessed in the absence of primary mAb and subtracted
from all samples. Mean fluorescence values were obtained in at least
triplicate on a FACScalibur (BD Biosciences-PharMingen), and data
were analyzed with Cell Quest software.

Kinetic Analysis of mLRP4 Endocytosis
Fifty micrograms of RAP were iodinated using the Iodogen method
as described (Bu et al., 1992). Kinetic analysis of endocytosis was
performed essentially as described (Li et al., 2000, 2001a). Briefly,
CHO-mLRP4 cells were plated in 12-well plates at a density of 2 ⫻
105 cells/well and used after overnight culture. Cells were pretreated in the presence or absence of MG132 (20 M) for either 30
min or 2 h. 125I-RAP was added at 5 nM final concentrations in cold
ligand binding buffer (0.5 ml/well). The binding of 125I-RAP was
carried out at 4°C for 30 min with gentle rocking. Unbound ligand
was removed by washing cell monolayers three times with cold
binding buffer. Ice-cold stop/strip solution (0.2 M sodium acetate/
acetic acid, pH 2.6, 0.1 M NaCl) was added to one set of plates
without warming up. The remaining plates were then placed in a
37°C water bath, and 0.5 ml of ligand binding buffer with or without
MG132 and prewarmed to 37°C was quickly added to the cell
monolayers to initiate internalization. After each time point, the
plates were quickly placed on ice and the ligand binding buffer was
replaced with cold stop/strip solution. Ligand that remained on the
cell surface was stripped by incubation of cell monolayers with cold
stop/strip solution for a total of 20 min (0.75 ml for 10 min, twice)
and counted. Cell monolayers were then solubilized with low-SDS
lysis buffer (62.5 mM Tris-HCl, pH 6.8, 0.2%SDS, 10% vol/vol
glycerol, and 0.02% bromophenol blue) and counted in a ␥ counter.
The sum of ligand that was internalized plus that remained on the
cell surface after each assay was used as the maximum potential
internalization. The fraction of internalized ligand after each time
point was calculated and plotted.
Figure 1. The proteasomal inhibitor MG132 prolongs the cellular
half-life of LRP. (A) HepG2 cells were metabolically labeled with
[35S]cysteine for 30 min and chased for the indicated times, in the
absence or presence of MG132 (20 M). After each chase, cell lysates
were immunoprecipitated with anti-LRP antibody and analyzed
with SDS gels (5%) under reducing conditions. The 200-kDa molecular size marker is indicated. (B) The band intensities in A were
quantitated and plotted against chase times.

in each experiment. Cell monolayers were then washed twice in
prechilled PBSc and lysed with 0.5 ml of lysis buffer. Equal quantities of protein were subjected to SDS-PAGE (6%) under reducing
conditions. After transfer to PVDF membrane, successive incubations with anti-HA antibody and horseradish peroxidase– conjugated goat anti-mouse IgG were carried out for 60 min at room
temperature. The immunoreactive proteins were then detected using the ECL system. Films showing immunoreactive bands were
scanned by Kodak Digital Science DC120 Zoom Digital Camera and
analyzed with Kodak Digital Science1D Image Analysis Software
(Eastman-Kodak, Rochester, NY).

Flow Cytometric Analysis of Cell Surface LRP
Minireceptors
CHO-mLRP4 cells were seeded at 1.2 ⫻ 106 cells per T25 flask and
cultured overnight before experiments. Cells were washed in se-
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Uptake of Cy3-labeled Ligands and Confocal
Immunofluorescence Microscopy
Ts20-mLRP4 or ts20-GHR cells were grown on glass coverslips
overnight before experiments. Cells were then incubated at 30, 41.5,
or at 30°C with either DMSO or DMSO containing 20 M MG132 for
1 h. Incubation was continued for 10 min with Cy3-RAP (20 nM) or
30 min with Cy3-GH (8 nM) at 30 or 41.5°C. After medium aspiration, cells were washed once with PBS and once with fixative (3%
paraformaldehyde in 0.1 M sodium phosphate, pH 7.2), fixed for 3 h
in fixative, washed with PBS and water, and embedded in Mowiol.
The laser scanning microscopy was performed using a Leica TCS 4D
system and 63⫻ oil immersion lens (Bensheim, Germany).

Uptake and Degradation of Radiolabeled Ligands
Iodinated uPA-PAI-1 complexes were added to vehicle or drugpretreated cells as described above. Radiolabeled ligand with or
without excess unlabeled RAP (0.5 M) was incubated for 4 h at
37°C. The overlying media were collected from cells and precipitated with 20% trichloroacetic acid (TCA). TCA soluble counts, after
subtraction of TCA-soluble counts in well contained no cells, were
used to represent cell-mediated degradation of radiolabeled ligand.
Unbound ligand was removed by washing cell monolayers three
times with cold binding buffer. Ligand that remained on the cell
surface was stripped by incubation of cell monolayers with cold
stop/strip solution for a total of 20 min and counted. Cell mono-
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Figure 2. The proteasomal inhibitor MG132 increases the half-life of
a LRP minireceptor, mLRP4. CHOmLRP4 cells were metabolically labeled with [35S]cysteine for 30 min
and chased for the indicated times,
in the absence or presence of MG132
(20 M). After each chase, cell lysates were immunoprecipitated
with anti-HA antibody and analyzed with SDS gels (6%) under reducing conditions. The molecular
size markers in this and subsequent
figures are given in kilodaltons on
the left. The positions of the precursor and the mature forms of mLRP4
are marked. (B) The band intensities
in A (includes the precursor and the
mature forms) were quantitated and
plotted against chase time.

layers were then washed twice in PBSc and lysed in low-SDS buffer
to quantitate cell-associated ligand.

Immunoelectron Microscopy
CHO-mLRP4 cells were incubated in the absence or presence of 20
M MG132 for 2 h and thereafter fixed in a mixture of 2% paraformaldehyde and 0.5% glutaraldehyde in 0.1 M phosphate buffer, pH
7.4, for 1 h and then stored in the same buffer containing 1%
paraformaldehyde until use. Cryosections of 50 –100 nm were
picked up from the diamond knife in a sucrose/methylcellulose
mixture and sequentially incubated with mouse monoclonal HA
antibody, polyclonal rabbit anti-mouse IgG (Dako, Copenhagen,
Denmark), and 10-nm protein A– conjugated gold particles (for
technical details see Kleijmeer et al., 1996). mLRP4 labeling at the cell
surface was quantitatively evaluated in a total of 50 electron micrographs at ⫻15,000 taken randomly from sections of two blocks with
control and two blocks of MG132-treated cells. Totals of gold particles and measured plasma membrane lengths in control cells and
MG132 cells were 680/969 and 1733/949 m, respectively. mLRP4
labeling densities represented by the ratios of gold particles over
plasma membrane length were 0.76 ⫾ 1.12 and 1.78 ⫾ 2.08 (means ⫾
SD) in control and MG132 cells, respectively.

RESULTS
Inhibition of Proteasome Activity Increases the
Half-Life and the Steady State Levels of LRP
To determine whether proteasomal inhibitors influence the
cellular turnover of LRP, we analyzed the half-life of LRP in
the absence or presence of the proteasome inhibitor MG132
in HepG2 cells. These cells were metabolically pulse labeled
with [35S]cysteine for 30 min and chased for 0.5, 1, 2, 4, or
8 h, in the absence or presence of MG132 (20 M). After each
chase time, cell lysates were quantitatively immunoprecipitated with anti-LRP antibody and analyzed by SDS-PAGE
under reducing conditions (Figure 1A). When the band in3328

tensities were quantitated with a phosphorimager, we found
that the half-life of LRP is prolonged from ⬃3 h in the
absence of MG132 to ⬎8 h in the presence of MG132 (Figure
1B). Similar results were obtained when lactacystein, was
used as the proteasomal inhibitor.
Many of our recent studies on LRP endocytosis and trafficking have been carried out mostly using a minireceptor
form of LRP, which includes the fourth ligand-binding domain and the entire carboxyl-terminus of the receptor (Li et
al., 2000, 2001a, 2001b; Obermoeller-McCormick et al., 2001).
This receptor, referred to as mLRP4, exhibits similar biogenesis and trafficking with the endogenous full-length receptor, including the furin cleavage to generate the two subunits (Li et al., 2001a; Obermoeller-McCormick et al., 2001).
One advantage of this minireceptor is the ability to readily
distinguish the mature form from the precursor form of the
protein, which is extremely difficult for the endogenous
full-length LRP because of its large size (Obermoeller-McCormick et al., 2001). Additionally, mLRP4 is tagged with an
HA epitope near its amino-terminus, which facilitates various immunodetection strategies including immunoelectron
microscopy (see below). To examine whether the cellular
turnover of mLRP4 is also regulated by the proteasome, we
performed metabolic pulse-chase labeling with mLRP4 stably expressed in CHO LRP-null cells (FitzGerald et al., 1995;
stable cell line is termed CHO-mLRP4). Seen in Figure 2 are
results from a representative experiment. As seen in the
figure, the presence of MG132 significantly increased the
half-life of the mature forms of mLRP while exhibiting little
effect on the precursor form; the half-life of mLRP4 was
increased from ⬃2.5 to ⬃5.5 h. To exclude the possibility
that the effect of proteasome inhibitor on the half-life mLRP4
was due to the different cell lines used in our studies, we also
performed pulse chase experiments to examine mLRP4 halflife in mLRP4-transiently transfected HepG2 cells. We found
Molecular Biology of the Cell
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Figure 3. Treatment of CHO-mLRP4 cells with proteasomal inhibitors increases the steady state levels of mLRP4. (A) CHO-mLRP4
cells were treated with either vehicle DMSO or DMSO containing
MG132 (20 M) for various periods of time. Equal quantities of cell
lysates were separated via SDS gel (6%) and blotted with anti-HA
antibody. Only the precursor form and the ligand-binding subunit
of the mature form are detected in the blot because these forms, but
not the 85-kDa subunit mature form, contain the HA epitope. Note
the increase of the mature form, but not the precursor form of
mLRP4 after MG132 treatment. (B) The effects of proteasomal inhibition on steady state levels of mLRP4 were also seen with lactacystin, but not with vehicle DMSO alone.

that MG132 increased the half-life of mLRP4 in HepG2 cells
from ⬃4.2 to 8.1 h. These results demonstrate that the proteasome inhibitor MG132 increases the half-life of mLRP4 in
both CHO LRP-null cells and HepG2 cells.
To examine whether an increase of mLRP4 half-life results
in an increase in the steady state level of mLRP4, we treated
CHO-mLRP4 cells for various periods of time and analyzed
the total cellular mLRP4 via Western blotting with anti-HA
antibody. Only the precursor form and the ligand-binding
subunit of the mature form are shown in the blot because
these forms, but not the 85-kDa subunit mature form, contain the HA epitope. As seen in Figure 3A, a significant
increase of the mature form, which is present at the cell
surface and later compartments of the endocytic pathway, is
seen in the presence of MG132. An average of ⬃2.5-fold
increase of mature mLRP4 was consistently observed using
this method. The increase in steady state level of mLRP4 was
also seen upon incubation with lactacystin but not with the
vehicle DMSO alone (Figure 3B). These results suggest that
the cellular turnover of LRP is mediated via or regulated by
proteasomal activity.

Treatment of Cells with Proteasomal Inhibitors also
Increased Cell Surface mLRP4
To analyze whether upon treatment of cells with proteasome
inhibitors there was also a change of cell surface mLRP4, we
performed FACS analysis using the anti-HA antibody. As
seen in Figure 4A, we consistently observed an approxiVol. 13, September 2002

Figure 4. Proteasomal inhibitors increase cell surface mLRP4. (A)
CHO-mLRP4 cells were treated with DMSO or DMSO containing
MG132 (20 M) for 2 h. Cells were then dissociated and immunostained with anti-HA antibody. Cell surface mLRP4 was detected
with goat anti-mouse Ig-FITC and FACS analysis. Background fluorescence intensity was assessed in the absence of primary antibody
and subtracted from each assay. The mean values from representative triplicate determinations were averaged with the SE value
given as error bars. (B) Kinetic analyses of cell surface mLRP4 after
treatment with proteasomal inhibitors. CHO-mLRP4 cells were
treated with MG132 (20 M) for various periods of time as indicated. Treatment with the alternative proteasome inhibitor lactacystin (20 M) or vehicle DMSO alone were also performed at selected
time points. Cell surface mLRP4 was determined via FACS analysis
as indicated above. Shown in the figure are results of a representative experiment. Note the gradual increase of cell surface mLRP4
upon treatment with proteasomal inhibitors, but not DMSO.

mately threefold increase (average of 5 experiments) of cell
surface mLRP4 after a 2-h treatment of CHO-mLRP4 cells
with MG132. To examine the kinetics of the cell surface
increase of mLRP4, we treated CHO-mLRP4 cells with
MG132 for increasing periods of time and measured cell
surface mLRP4 via FACS analyses. Shown in Figure 4B are
results from a representative experiment. As seen in the
figure, there is a gradual increase of cell surface mLRP4
upon MG132 treatment, suggesting that the cell surface increase of mLRP4 is cumulative. A similar increase in cell
3329
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Figure 5. The initial endocytosis of mLRP4 is slowed, but not
blocked by proteasomal inhibitors. CHO-mLRP4 cells were pretreated with DMSO or DMSO containing MG132 (20 M) for either
30 min (A) or 2 h (B). The initial endocytosis rates of mLRP4 were
measured using 125I-RAP as described in MATERIALS AND
METHODS. Data represent triplicate determination with SE values
given as error bars.

surface mLRP4 was also observed, at the selected time
points, with lactacystin, but not with vehicle DMSO alone
(Figure 4B). These results suggest that proteasomal inhibitors likely block LRP trafficking at an endosomal compartment (e.g., sorting endosome) from which the receptor is still
able to recycle to the cell surface.

Proteasomal Inhibitors Slow, but Do Not Block the
Initial Endocytosis of mLRP4
Recent studies have shown that the proteasome regulates
not only the degradation but also the initial endocytosis of
several cell surface receptors including the GHR (van Kerkhof et al., 2000). To determine whether the endocytosis of
mLRP4 is regulated by proteasomal activity, we quantitated
the initial endocytosis rate of mLRP4 after pretreatment of
cells with MG132 for either 30 min (Figure 5A) or 2 h (Figure
5B). As seen in Figure 5A, there was no significant change of
mLRP4 endocytosis rate when cells were pretreated with
MG132 for only 30 min. However, a significant (⬃40%)
decrease in mLRP4 endocytosis rate was seen when cells
3330

were pretreated for 2 h with MG132 (Figure 5B). It is important to point out that although the initial (ⱕ30 s) endocytosis
rate was decreased in the presence of MG132, the overall
ability of mLRP4 to endocytose ligands was essentially indistinguishable in the absence or presence of MG132 when
endocytosis evaluated ⬎120 s.
To determine whether a functional ubiquitin system is
required for LRP-mediated endocytosis, we compared the
endocytosis of ligands for mLRP4 (RAP) and GHR (GH) in
ts20 cells stably expressing mLRP4 (ts20-mLRP4) or GHR
(ts20-GHR). The ts20 cells express a thermolabile, ubiquitinactivating enzyme, E1 (Kulka et al., 1988; Handley-Gearhart
et al., 1994). At the permissive temperature (30°C), both
Cy3-RAP (Figure 6A) and Cy3-GH (Figure 6B) were endocytosed. However, at the nonpermissive temperature
(41.5°C), wherein the ubiquitin activating enzyme is inactivated, Cy3-RAP (Figure 6C), but not Cy3-GH (Figure 6D),
were internalized. This indicates that the initial endocytosis
of GHR, but not mLRP4, requires a functional ubiquitinactivating/conjugating system (Strous et al., 1996). Using
similar assays at the permissive temperature, we also found
that the proteasomal inhibitor, MG132, inhibits the endocytosis of GH (Figure 6F), but not RAP (Figure 6E), consistent
with our previous observation that the initial endocytosis of
the GHR, but not mLRP4, requires proteasomal activity (van
Kerkhof et al., 2000; also see Figure 5). We confirmed the
clathrin-dependence of mLRP4 and GHR endocytosis because potassium-depletion inhibited Cy3-RAP and Cy3-GH
endocytosis.
Our previous studies have shown that mLRP4 is capable
of binding and endocytosing several LRP ligands, including
uPA-PAI-1 complexes (Obermoeller-McCormick et al., 2001).
To examine the fate of mLRP4 ligands in the absence or
presence of proteasomal inhibitors, we performed ligand
uptake and degradation assays using CHO-mLRP4 cells. In
this experiment, 125I-uPA-PAI-1 was incubated with CHOmLRP4 cells at 37°C for 4 h. Cell-mediated degradation and
intracellular and cell surface bound ligands were determined at the end of assay. As seen in Figure 7A, MG132
significantly inhibited cellular degradation of 125I-uPAPAI-1. A corresponding increase of intracellular 125I-uPAPAI-1 was seen (Figure 7B), suggesting that the block in
125
I-uPA-PAI-1 degradation likely involves inhibition of ligand delivery to the lysosomal compartment. A small increase in cell surface 125I-uPA-PAI-1 was also observed (Figure 7C), consistent with the fact that MG132 slows mLRP4mediated endocytosis (see Figure 5). Taken together, these
results indicate that proteasomal activity is required for
intracellular trafficking of mLRP4 and its ligand to the degradation pathway.

Trafficking of mLRP4 to the Multivesicular Bodies
Is Blocked on Proteasome Inhibition
To examine morphologically the effects of proteasome inhibitors on LRP endocytic trafficking, we performed immunogold EM labeling of mLRP4 in MG132-treated and control
cells. Differences in mLRP4 labeling between control and
MG132 cells mainly concerned the plasma membrane and
late endocytic compartments. First, in control cells most of
the surface mLRP4 was localized to clathrin-coated pits (Figure 8A), similar to what we have observed previously for the
endogenous LRP (Bu et al., 1994). However, in MG132Molecular Biology of the Cell
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Figure 6. A functional ubiquitin conjugation system is not required for mLRP4-mediated endocytosis. CHO-ts20-mLRP4 or
CHO-ts20-GHR cells were incubated with Cy3-RAP (20 nM) for 10
min or Cy3-GH for 30 min, respectively, under the conditions
indicated. Cells were washed, fixed, and examined with a confocal
microscope. At the permissive temperature (30°C), endocytosis of
both Cy3-RAP (A) and Cy3-GH (B) is observed by the appearance of
punctuate fluorescence representing ligand distribution in endocytic compartments. The endocytosis of Cy3-GH, but not Cy3-RAP,
was inhibited at the nonpermissive temperature (41.5°C), and in the
presence of the proteasomal inhibitor MG132 (C-F).

treated cells, mLRP4 is observed in both clathrin-coated pits,
and outside the pits (Figure 8, B and E). A quantitative
evaluation of the labeling at the plasma membrane revealed
a statistically significant 2.5-fold greater labeling density of
mLRP4 in MG132 cells than in control cells (see MATERIALS AND METHODS for quantitation results). Second,
mLRP4 in control cells was found throughout the endocytic
pathway, i.e., primary endocytic vesicles, multivesicular
bodies (MVBs; Figure 8, C and D), and lysosomes. Within
the MVBs, mLRP4 labels were associated with both the
limiting membrane and the internal vesicles, thought to be
destined for degradation (Gruenberg, 2001). The limiting
membrane showed triple-layered, clathrin-coated lattices,
likely involved in the recruitment of membrane proteins for
Vol. 13, September 2002

Figure 7. Treatment of CHO-mLRP4 cells with proteasomal inhibitors results in intracellular accumulation and inhibition of degradation of mLRP4 ligand. 125I-uPA-PAI-1 (2 nM) was incubated with
CHO-mLRP4 cells at 37°C for 4 h. Cell-mediated degradation and
intracellular and cell surface bound ligands were determined as
described in MATERIALS AND METHODS. Data represent triplicate determinations with SE values given as error bars.

targeting to the internal vesicles (Sachse et al., 2002). In
contrast, MG132 cell profiles showed no or few MVBs with
scarce mLRP4 labeling. Instead, mLRP4 was found intensely
in long peripheral tubules, probably representing early endosomes/recycling tubules (Figure 8E).

Residues 60 –78 of the LRP Tail Are Required for
Proteasomal Regulation
To begin to identify cis-elements within the LRP tail that are
required for proteasomal regulation, we examined the effects of MG132 treatment on CHO LRP-null cells stably
expressing various tail-truncation mutants of mLRP4 (Li et
al., 2000). As seen in Figure 9A, upon MG132 treatment
increase of cell surface mLRP4 was nearly abolished when
the tail is truncated to 59 amino acid residues but not when
truncated to 78 amino acids. To examine whether these
differences in response to MG132 also apply to the steady
state levels of these truncated minireceptors, we compared
their steady state levels in the absence or presence of MG132
treatment. As seen in Figure 9B, each of these mLRP4 minireceptors is expressed at a similar basal level when the
3331
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Figure 8. Proteasome inhibitors increase surface localization of mLRP4 and block the delivery of mLRP4 into MVBs. Cryosections of
CHO-mLRP4 cells were immunogold labeled with anti-HA antibodies and 10 nm gold particles. (A, C, and D) control cells; (B and E)
MG132-treated cells. In control cells (A) by far the majority of mLRP4 at the plasma membrane is present in clathrin-coated pits, whereas in
cells treated with MG132 (B and E) label is also present outside the pits. (C and D) MVBs in control cells with label present at the limiting
membrane and associated with the internal vesicles. Note the thick clathrin lattices at the limiting membrane (arrows). (E) Peripheral
cytoplasm of a MG132-treated cell with labeled clathrin-coated vesicles and long recycling tubules (arrowheads). All bars represent 200 nm.

precursor forms are compared. The increased ratios of mature to precursor forms for mLRP4Tailess and mLRP4T59
when compared with that of mLRP4T100 are due to the
3332

slower endocytosis rates mediated by these two truncated
minireceptors (Li et al., 2000). More importantly, we demonstrated that the proteasome inhibitor MG132 increased the
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Figure 9. The increase in cell surface mLRP4 upon MG132 treatment requires residues 60 –78 of the LRP tail. CHO LRP-null cells
stably transfected with cDNAs of mLRP4(T100), mLRP4T78,
mLRP4T59, or mLRP4T tailess (Li et al., 2000) were treated with
DMSO or DMSO containing MG132 (20 M) for 2 h at 37°C. (A) Cell
surface mLRP4 minireceptor levels were determined as described in
Figure 4. Values are the average of triple determinations with the SE
value indicated by error bars. (B) The steady state levels of mLRP4
minireceptors were analyzed as described in Figure 3.

steady state levels of the mature forms of mLRP4T78 and
mLRP4T100 but not those of mLRP4Tailess and mLRP4T59.
These results together suggest that the region of the tail
between amino acids 60 and 78 may contain an important
sequence or binding site that when present contributes to
mLRPs regulation by the proteasome. Additionally, because
mLRP4T59 still exhibits significant endocytosis (Li et al.,
2000), but is minimally regulated by the proteasome, the
results further suggest that the endocytosis and proteasomal
regulation of LRP are separate events.

DISCUSSION
LRP has emerged as a unique receptor in the LDLR family in
several aspects. First, LRP is a multifunctional receptor with
the ability to bind ⬎30 distinct ligands (Herz and Strickland,
2001). Second, its endocytosis is significantly faster than
other members of the LDLR family (Li et al., 2001a, 2001b).
Third, its physiological functions are carried out by both
receptor-mediated endocytosis and signal transduction
(Herz, 2001). The high level expression of this LRP in the
brain and liver as well as its multiligand nature are consistent with its requirement for normal embryonic growth and
development (Herz et al., 1992, 1993). Additionally, imporVol. 13, September 2002

tant roles for LRP in the pathogenesis of disease (e.g., Alzheimer’s disease) have recently been recognized (Hyman et
al., 2000; Kang et al., 2000). However, despite advances in
understanding the biogenesis of this giant receptor, including the role of its intracellular chaperone RAP (Bu, 2001),
little is known about the mechanisms governing its cellular
turnover.
In this study, we demonstrate that inhibition of proteasomal activity results in an increase of cellular half-life of LRP
and its minireceptor mLRP4. Additionally, we showed that
proteasomal inhibitors block the trafficking of mLRP4 into
MVBs. The block in mLRP4 trafficking to the MVBs was also
indicated as the mLRP4, which accumulated in the presence
of proteasome inhibitors, recycled back to the cell surface.
Thus, we conclude that the trafficking of LRP to the degradation pathway is regulated by proteasomal activity. The
importance of the proteasome activity in receptor trafficking
to the degradation pathway has also been shown recently
for the EGFR (Longva et al., 2002). In that case, inhibition of
proteasome also blocked receptor degradation and promoted receptor recycling (Longva et al., 2002).
Cell surface receptors entering sorting endosomes can be
either recycled to the plasma membrane or degraded via
delivery to the lysosome (Lemmon and Traub, 2000; Gruenberg, 2001). Increasing evidence has shown that the recycling of receptors is the default pathway, whereas delivery
to the degradation pathway is signal mediated. Critical step
in the latter process occurs in the MVBs where the limiting
membrane invaginates and buds into the lumen of the
MVBs/late endosome (Gruenberg, 2001; Gruenberg and
Maxfield, 1995). One of the best-studied examples of this
sorting process is the downregulation of the EGFR. On EGF
activation, the delivery of the EGFR to the MVBs/late endosome requires sorting signals within the EGFR tail and the
ubiquitin ligase c-Cbl (Levkowitz et al., 1998, 1999). Recently,
it has been shown that the ubiquitin-dependent sorting into
the MVBs pathway requires the function of a conserved
endosomal protein sorting complex, ESCRT-1 (Katzmann et
al., 2001). This complex, composed of three products of the
class E vacuolar protein sorting (VPS) genes (Vps23, Vps 28,
and Vps 37), recognizes ubiquitinated cargo molecules and
initiates their sorting into the lumen of the MVBs. Thus, one
approach to define the mechanism of LRP downregulation
by the ubiquitin–proteasome system is to determine
whether the cytoplasmic tail of this receptor can be ubiquitinated. Despite a recent report that suggests that the extracellular subunit of LRP can be ubiquitinated (Misra and
Pizzo, 2001), we have failed to detect any ubiquitination of
LRP after an extensive series of approaches, including both
in vivo immunodetection of ubiquitinated LRP species in the
presence of proteasomal inhibitors and in vitro ubiquitination assays of GST-LRP tail fusion proteins (Li et al., 2001b).
These results suggest that an ancillary protein, which itself
may be ubiquitinated and thus regulated by the ubiquitin–
proteasome system, may function as a regulatory protein for
LRP turnover. In support of this hypothesis, we show herein
that a region of the LRP tail (residue 60 –78) is required for
its proteasomal regulation. It is possible that this region of
the LRP tail contains a sequence element important for
interaction with the regulatory protein, perhaps similar to
that in the growth hormone receptor (Govers et al., 1999) or
␤-arrestin, associated with the ␤2-adrenergic receptor (She3333
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noy et al., 2001). An alternative mechanism underlying proteasomal regulation of LRP may involve a short-lived protein that functions in endosomal sorting and is regulated by
the proteasome.
Our previous studies have shown that a functional ubiquitin conjugation system is required for the initial endocytosis of the GHR (Strous et al., 1996). The likely mechanism
appears to be that the ubiquitination of an ancillary protein
that interacts with GHR and serves as the endocytosis signal
for the receptor. Our current study shows that such a functional ubiquitination system is not required for LRP endocytosis. This is not surprising because recent studies have
shown that the rapid endocytosis of LRP is mediated by
both a tyrosine-based signal as well as a di-leucine motif (Li
et al., 2000). The slower endocytosis of LRP seen upon prolonged treatment of cells with proteasomal inhibitors may
be due to an indirect effect of the inhibitors on the turnover
of some component(s) of the endocytic machinery. However, the initial endocytosis of the transferrin receptor is not
affected by these same proteasomal inhibitors. This suggests
that the mechanism(s) underlying LRP endocytosis may utilize partially a distinct mechanism for its rapid endocytosis.
The need for downregulation of signal transducing receptors is for signal desensitization. However, the significance
of downregulation of receptors whose primary function is
cargo transport is less clear. Receptors such as the LDLR and
the transferrin receptor, whose sole recognized function is
cargo transport, typically exhibit long half-lives (Goldstein et
al., 1985). While examining the turnover of LRP in various
cell types, we noted half-lives ranging from 3.5 h in HepG2
cells to ⬎8 h in U87 cells (Bu et al., 1994). Thus, the function
of LRP in cargo transport and/or signal transduction may
vary among cell types and/or in the presence of different
ligands. LRP may represent a distinct class of receptor with
both cargo transport as well as signal transduction activity)
whose cellular turnover is regulated by more than one
mechanism. In this regard it is tempting to speculate that the
regulation of LRP endocytic trafficking is also unique and
may involve both a specific cis-element within its cytoplasmic tail, as well as an unidentified cytosolic protein that
recognizes this tail element.
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